Aortic insufficiency medical management: Difference between revisions
Jump to navigation
Jump to search
Varun Kumar (talk | contribs) No edit summary |
Varun Kumar (talk | contribs) No edit summary |
||
| Line 11: | Line 11: | ||
Long term therapy with [[nifedipine]] and [[hydralazine]] have shown to increase left ventricular ejection fraction, reduce left ventricular end diastolic volume and reduction in left ventricular mass thereby delaying the need for valve surgery <ref name="pmid8058074">{{cite journal |author=Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S |title=Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function |journal=[[The New England Journal of Medicine]] |volume=331 |issue=11 |pages=689–94 |year=1994 |month=September |pmid=8058074 |doi=10.1056/NEJM199409153311101 |url=http://dx.doi.org/10.1056/NEJM199409153311101 |accessdate=2011-03-23}}</ref> <ref name="pmid3289791">{{cite journal |author=Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson RA, Szlachcic J, Thomas D |title=Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial |journal=[[Circulation]] |volume=78 |issue=1 |pages=92–103 |year=1988 |month=July |pmid=3289791 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=3289791 |accessdate=2011-03-23}}</ref> <ref name="pmid2197314">{{cite journal |author=Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S |title=Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation |journal=[[Journal of the American College of Cardiology]] |volume=16 |issue=2 |pages=424–9 |year=1990 |month=August |pmid=2197314 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(90)90596-H |accessdate=2011-03-23}}</ref>. While [[ACE inhibitor]]s such as enalapril and quinapril have shown to decrease left ventricular mass and end diastolic volume but with no influence on ejection fraction <ref name="pmid7930196">{{cite journal |author=Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, Cheitlin MD |title=Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy |journal=[[Journal of the American College of Cardiology]] |volume=24 |issue=4 |pages=1046–53 |year=1994 |month=October |pmid=7930196 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(94)90868-0 |accessdate=2011-03-23}}</ref> <ref name="pmid8000584">{{cite journal |author=Schön HR, Dorn R, Barthel P, Schömig A |title=Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation |journal=[[The Journal of Heart Valve Disease]] |volume=3 |issue=5 |pages=500–9 |year=1994 |month=September |pmid=8000584 |doi= |url= |accessdate=2011-03-23}}</ref> | Long term therapy with [[nifedipine]] and [[hydralazine]] have shown to increase left ventricular ejection fraction, reduce left ventricular end diastolic volume and reduction in left ventricular mass thereby delaying the need for valve surgery <ref name="pmid8058074">{{cite journal |author=Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S |title=Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function |journal=[[The New England Journal of Medicine]] |volume=331 |issue=11 |pages=689–94 |year=1994 |month=September |pmid=8058074 |doi=10.1056/NEJM199409153311101 |url=http://dx.doi.org/10.1056/NEJM199409153311101 |accessdate=2011-03-23}}</ref> <ref name="pmid3289791">{{cite journal |author=Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson RA, Szlachcic J, Thomas D |title=Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial |journal=[[Circulation]] |volume=78 |issue=1 |pages=92–103 |year=1988 |month=July |pmid=3289791 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=3289791 |accessdate=2011-03-23}}</ref> <ref name="pmid2197314">{{cite journal |author=Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S |title=Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation |journal=[[Journal of the American College of Cardiology]] |volume=16 |issue=2 |pages=424–9 |year=1990 |month=August |pmid=2197314 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(90)90596-H |accessdate=2011-03-23}}</ref>. While [[ACE inhibitor]]s such as enalapril and quinapril have shown to decrease left ventricular mass and end diastolic volume but with no influence on ejection fraction <ref name="pmid7930196">{{cite journal |author=Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, Cheitlin MD |title=Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy |journal=[[Journal of the American College of Cardiology]] |volume=24 |issue=4 |pages=1046–53 |year=1994 |month=October |pmid=7930196 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0735-1097(94)90868-0 |accessdate=2011-03-23}}</ref> <ref name="pmid8000584">{{cite journal |author=Schön HR, Dorn R, Barthel P, Schömig A |title=Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation |journal=[[The Journal of Heart Valve Disease]] |volume=3 |issue=5 |pages=500–9 |year=1994 |month=September |pmid=8000584 |doi= |url= |accessdate=2011-03-23}}</ref> | ||
==AHA guidelines for use of Vasodilator therapy in Chronic Aortic Insufficiency== | Patients with severe aortic insufficiency with normal left ventricular function are recommended to undergo surgery though there are no sufficient evidences against medical management. | ||
Use of other drugs other than [[vasodilators]], such as [[digoxin]], [[diuretics]] and other positive [[inotropic]] drugs for long term treatment have no supportive data. | |||
==ACC/AHA guidelines for use of [[Vasodilator]] therapy in Chronic severe Aortic Insufficiency== | |||
{{cquote|'''Class I''' | {{cquote|'''Class I''' | ||
Vasodilator therapy is indicated for chronic therapy in patients with severe | Vasodilator therapy is indicated for chronic therapy in patients with severe aortic insufficiency who have symptoms or left ventricular dysfunction when surgery is not recommended because of additional cardiac or noncardiac factors. | ||
'''Class IIa''' | '''Class IIa''' | ||
Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with severe heart failure symptoms and severe | Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with severe heart failure symptoms and severe left ventricular dysfunction before proceeding with [[aortic valve replacement]]. | ||
'''Class IIb''' | '''Class IIb''' | ||
Vasodilator therapy may be considered for long-term therapy in asymptomatic patients with severe | Vasodilator therapy may be considered for long-term therapy in asymptomatic patients with severe aortic insufficiency who have left ventricular dilatation but normal systolic function. | ||
'''Class III''' | '''Class III''' | ||
# Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with mild to moderate | # Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with mild to moderate aortic insufficiency and normal left ventricular systolic function. | ||
# Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with | # Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with left ventricular systolic dysfunction who are otherwise candidates for [[aortic valve replacement]]. | ||
# Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal | # Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal left ventricular function or mild to moderate left ventricular systolic dysfunction who are otherwise candidates for [[aortic valve replacement]].}} | ||
==References== | ==References== | ||
Revision as of 14:44, 24 March 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Medical therapy of chronic aortic insufficiency involves the use of vasodilators. Small trials have demonstrated a benefit from the administration of ACE inhibitors, nifedipine, sodium nitroprusside and hydralazine in improving left ventricular wall stress, ejection fraction, and left ventricular mass [1] [2] [3] [4]. The use of these vasodilators is indicated only in those individuals who suffer from hypertension in addition to aortic insufficiency. The goal in using these pharmacologic agents is to decrease the afterload so that the left ventricle is unloaded. This results in reduction in left ventricular end diastolic pressure thereby preserving the left ventricular systolic function and also benefits the patients in left ventricular failure secondary to aortic insufficiency.
Long term therapy with nifedipine and hydralazine have shown to increase left ventricular ejection fraction, reduce left ventricular end diastolic volume and reduction in left ventricular mass thereby delaying the need for valve surgery [5] [6] [7]. While ACE inhibitors such as enalapril and quinapril have shown to decrease left ventricular mass and end diastolic volume but with no influence on ejection fraction [8] [9]
Patients with severe aortic insufficiency with normal left ventricular function are recommended to undergo surgery though there are no sufficient evidences against medical management.
Use of other drugs other than vasodilators, such as digoxin, diuretics and other positive inotropic drugs for long term treatment have no supportive data.
ACC/AHA guidelines for use of Vasodilator therapy in Chronic severe Aortic Insufficiency
| “ | Class I
Vasodilator therapy is indicated for chronic therapy in patients with severe aortic insufficiency who have symptoms or left ventricular dysfunction when surgery is not recommended because of additional cardiac or noncardiac factors. Class IIa Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with severe heart failure symptoms and severe left ventricular dysfunction before proceeding with aortic valve replacement. Class IIb Vasodilator therapy may be considered for long-term therapy in asymptomatic patients with severe aortic insufficiency who have left ventricular dilatation but normal systolic function. Class III
|
” |
References
- ↑ Bolen JL, Alderman EL (1976). "Hemodynamic consequences of afterload reduction in patients with chronic aortic regurgitation". Circulation. 53 (5): 879–83. PMID 1260993. Retrieved 2011-03-23. Unknown parameter
|month=ignored (help) - ↑ Miller RR, Vismara LA, DeMaria AN, Salel AF, Mason DT (1976). "Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume". The American Journal of Cardiology. 38 (5): 564–7. PMID 983953. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ Greenberg BH, DeMots H, Murphy E, Rahimtoola S (1980). "Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency". Circulation. 62 (1): 49–55. PMID 7379285. Retrieved 2011-03-23. Unknown parameter
|month=ignored (help) - ↑ Fioretti P, Benussi B, Scardi S, Klugmann S, Brower RW, Camerini F (1982). "Afterload reduction with nifedipine in aortic insufficiency". The American Journal of Cardiology. 49 (7): 1728–32. PMID 7081058. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S (1994). "Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function". The New England Journal of Medicine. 331 (11): 689–94. doi:10.1056/NEJM199409153311101. PMID 8058074. Retrieved 2011-03-23. Unknown parameter
|month=ignored (help) - ↑ Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson RA, Szlachcic J, Thomas D (1988). "Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial". Circulation. 78 (1): 92–103. PMID 3289791. Retrieved 2011-03-23. Unknown parameter
|month=ignored (help) - ↑ Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S (1990). "Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation". Journal of the American College of Cardiology. 16 (2): 424–9. PMID 2197314. Retrieved 2011-03-23. Unknown parameter
|month=ignored (help) - ↑ Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, Cheitlin MD (1994). "Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy". Journal of the American College of Cardiology. 24 (4): 1046–53. PMID 7930196. Retrieved 2011-03-23. Unknown parameter
|month=ignored (help) - ↑ Schön HR, Dorn R, Barthel P, Schömig A (1994). "Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation". The Journal of Heart Valve Disease. 3 (5): 500–9. PMID 8000584. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help)